Literature DB >> 402162

Effect of glutaraldehyde treatment on enzyme-loaded erythrocytes.

J Deloach, S Peters, O Pinkard, R Glew, G Ihler.   

Abstract

In principle, enzyme-loaded erythrocytes can be used as a vehicle for enzyme replacement therapy in lysosomal storage diseases. Glutaraldehyde treatment renders these erythrocytes more resistant to lysis without inactivating the enzymes that have been entrapped inside them. Glutaraldehyde treatment does not prevent ingestion of enzyme-loaded erythrocytes by macrophages in vitro so that these cells can be used to deliver enzymes to lysosomes. In vivo, the glutaraldehyde-treated cells are quickly removed from the circulation by the spleen or liver. The degree of glutaraldehyde treatment allows the erythrocytes to be targeted either to the spleen (low glutaraldehyde concentrations) or to the liver (higher glutaraldehyde concentrations).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 402162     DOI: 10.1016/0304-4165(77)90332-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

Review 1.  Erythrocyte-mediated delivery of recombinant enzymes.

Authors:  Vincenzo Leuzzi; Luigia Rossi; Claudia Gabucci; Francesca Nardecchia; Mauro Magnani
Journal:  J Inherit Metab Dis       Date:  2016-03-30       Impact factor: 4.982

2.  Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model.

Authors:  E Zocchi; M Tonetti; C Polvani; L Guida; U Benatti; A De Flora
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

3.  Incorporation of glucocerebrosidase into Gaucher's disease monocytes in vitro.

Authors:  G L Dale; W Kuhl; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

Review 4.  Carrier erythrocytes. Clinical pharmacokinetic considerations.

Authors:  M Tonetti; A De Flora
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

5.  Design strategies and applications of circulating cell-mediated drug delivery systems.

Authors:  Yixue Su; Zhiwei Xie; Gloria B Kim; Cheng Dong; Jian Yang
Journal:  ACS Biomater Sci Eng       Date:  2015-03-12

6.  Engineering of erythrocyte-based drug carriers: control of protein release and bioactivity.

Authors:  Rongcong Luo; Shaillender Mutukumaraswamy; Subbu S Venkatraman; Björn Neu
Journal:  J Mater Sci Mater Med       Date:  2011-11-18       Impact factor: 3.896

Review 7.  Macromolecular Conjugate and Biological Carrier Approaches for the Targeted Delivery of Antibiotics.

Authors:  Nhan Dai Thien Tram; Pui Lai Rachel Ee
Journal:  Antibiotics (Basel)       Date:  2017-07-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.